Treatment of cancer cells overexpressing somatostatin receptors using ocreotide derivatives chelated to radioisotopes
US11541133B2 · kind B2 · utility
Assignees
Inventors
Key dates
| Filing date | Jan 12, 2018 |
| Grant date | Jan 3, 2023 |
| Priority date | — |
| Expiry date | Jan 12, 2038 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K45/06
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A cancer targeting composition, kit, and method for treatment of cancer cells overexpressing somatostatin receptors is disclosed. The composition includes a radioisotope, a chelator, and a targeting moiety. The chelator includes a nitrogen ring structure including a tetraazacyclododecane, a triazacyclononane, and/or a tetraazabicyclo [6.6.2] hexadecane derivative. The targeting moiety includes a somatostatin receptor targeting peptide. The somatostatin receptor targeting peptide includes an octreotide derivative. The targeting moiety is chelated to the radioisotope by the chelator whereby the cancer cells are targeted for elimination.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.